A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0

作者：

Advani, Anjali S. ^{[1
]}

Cooper, Brenda ^{[2
]}

Elson, Paul ^{[3
]}

Mukherjee, Sudipto ^{[4
]}

Fensterl, Jaime ^{[5
]}

Gerds, Aaron T. ^{[6
]}

Caimi, Paolo F. ^{[2
]}

Tomlinson, Ben K. ^{[2
]}

Malek, Ehsan ^{[7
]}

Little, Jane A. ^{[8
]}

Rush, Mary Lynn ^{[9
]}

Bogati, Samjhana ^{[10
]}

Parsons, Eric ^{[9
]}

Kane, Donna ^{[11
]}

Carraway, Hetty E. ^{[4
]}

Nazha, Aziz ^{[6
]}

Hamilton, Betty K. ^{[6
]}

Sobecks, Ronald ^{[12
]}

Bevier, Barbara ^{[9
]}

Goebel, Christopher ^{[9
]}

Zimmerman, Cassie ^{[9
]}

Nielsen, Alek D. ^{[13
]}

Hirsch, Cassandra M. ^{[13
]}

Maciejewski, Jaroslaw P. ^{[13
]}

Kalaycio, Matt ^{[4
]}

deLima, Marcos ^{[14
]}

Jacobberger, James ^{[15
]}

Woost, Philip ^{[15
]}

Sekeres, Mikkael A. ^{[4
,16
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[2] Univ Hosp Case Med Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA

[3] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH USA

[4] Cleveland Clin, Taussig Canc Inst Leukemia Program, Cleveland, OH USA

[5] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA

[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[7] Univ Hosp Case Med Ctr, Cleveland, OH USA

[8] Case Western Reserve Univ Univ Hosp Seidman Canc, Div Hematol Oncol, Cleveland, OH USA

[9] Cleveland Clin Leukemia Program, Taussig Canc Inst, Cleveland, OH USA

[10] Cleveland Clin Taussig Canc Inst, Taussig Canc Inst Leukemia Program, Cleveland, OH USA

[11] Univ Hosp Cleveland, Seidman Canc Ctr, Cleveland, OH USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA

[13] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[14] Univ Hosp, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA

[15] Case Western Reserve Univ, Cleveland, OH USA

[16] Cleveland Clin, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4065.4065

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4065

引用

页数：5

共 50 条

[1] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results
Advani, Anjali S.
Cooper, Brenda W.
Visconte, Valeria
Elson, Paul
Chan, E. Ricky
Carew, Jennifer
Mukherjee, Sudipto
Gerds, Aaron T.
Carraway, Hetty E.
Nazha, Aziz
Hamilton, Betty K.
Sobecks, Ronald
Caimi, Paolo
Tomlinson, Benjamin
Malek, Ehsan
Little, Jane A.
Fensterl, Jaime
Unger, Allison
Zimmerman, Cassie
Goebel, Christopher
Hoxha, Nita
Siebenaller, Caitlin
Thomas, Jenna
Rush, Mary Lynn
Bogati, Samjhana
Parsons, Eric
Diligente, Rachael
Kane, Donna
Nielsen, Alek
Hirsch, Cassandra M.
Edelheit, Simone
Miron, Alexander
Pink, John
Maciejewski, Jaroslaw P.
Kalaycio, Matt
De Lima, Marcos
Sekeres, Mikkael A.
BLOOD, 2017, 130
[2] APhase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Advani, Anjali S.
Cooper, Brenda
Visconte, Valeria
Elson, Paul
Chan, Ricky
Carew, Jennifer
Wei, Wei
Mukherjee, Sudipto
Gerds, Aaron
Carraway, Hetty
Nazha, Aziz
Hamilton, Betty
Sobecks, Ronald
Caimi, Paolo
Tomlinson, Benjamin
Malek, Ehsan
Little, Jane
Miron, Alexander
Pink, John
Maciejewski, Jaroslaw
Unger, Allison
Kalaycio, Matt
de Lima, Marcos
Sekeres, Mikkael A.
CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4231 - 4237
[3] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
Advani, Anjali
Elson, Paul
Hsi, Eric D.
Davis, Randall
Kalaycio, Matt
Sobecks, Ronald
Copelan, Edward
Duong, Hien K.
Foster, Bethany
Rush, Mary Lynn
Farhat, Leslie
Sekeres, Mikkael A.
BLOOD, 2012, 120 (21)
[4] Bortezomib plus MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial
Advani, Anjali S.
Elson, Paul
Kalaycio, Matt E.
Mukherjee, Sudipto
Gerds, Aaron T.
Hamilton, Betty K.
Hobson, Sean
Smith, Arian
Rush, Mary Lynn
Bogati, Samjhana
Biggins, Monique
Hsi, Eric D.
Duong, Hien K.
Copelan, Edward A.
Reu, Frederic J.
Saunthararajah, Yogen
Nazha, Aziz
Makishima, Hideki
Przychodzen, Bartlomiej
Dienes, Brittney
Maciejewski, Jaroslaw P.
Carew, Jennifer S.
Carraway, Hetty E.
Sekeres, Mikkael A.
BLOOD, 2014, 124 (21)
[5] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
Klisovic, Rebecca B.
Wang, Hongyan
Walker, Alison
Walsh, Katherine
Vasu, Sumithira
Garzon, Ramiro
Devine, Steven M.
Wang, Jiang
Garr, Celia
Norris, Adam
Byrd, John C.
Grever, Michael R.
Blum, William
Chan, Kenneth K.
Marcucci, Guido
BLOOD, 2012, 120 (21)
[6] A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Kuchroo, Manik Razdan
Redd, Robert A.
Garcia, Jacqueline S.
Keng, Michael
Hobbs, Gabriela S.
Rosenblatt, Jacalyn
Luskin, Marlise R.
Narayan, Rupa
Amrein, Philip C.
McMasters, Malgorzata
Wadleigh, Martha
Hock, Hanno
Stone, Richard
Neuberg, Donna S.
Avigan, David
Ballen, Karen K.
Fathi, Amir T.
DeAngelo, Daniel J.
Brunner, Andrew M.
BLOOD, 2023, 142
[7] Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia
Zhong, Sharon
Kurish, Heena
Walchack, Robert
Li, Hong
Edwards, Jessi
Singh, Abhay
Advani, Anjali
LEUKEMIA RESEARCH, 2024, 139
[8] Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.
Castagnola, C
Alessandrino, EP
Pagnucco, G
Bernasconi, P
Lunghi, M
Colombo, A
Brusamolino, E
Bonfichi, M
Corso, A
Lazzarino, M
Bernasconi, C
BLOOD, 2000, 96 (11) : 210B - 210B
[9] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
Halpern, Anna B.
Estey, Elihu H.
Othus, Megan
Orlowski, Kaysey F.
Powell, Morgan A.
Chen, Tara L.
Becker, Pamela S.
Scott, Bart L.
Hendrie, Paul C.
Ostronoff, Fabiana
Ranker, Elizabeth M.
Shadman, Mazyar
Stirewalt, Derek L.
Walter, Roland B.
BLOOD, 2014, 124 (21)
[10] Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia
Yamamoto, Chihiro
Ito, Shoko
Mashima, Kiyomi
Umino, Kento
Minakata, Daisuke
Yamasaki, Ryoko
Kawasaki, Yasufumi
Sugimoto, Miyuki
Nakano, Hirofumi
Ashizawa, Masahiro
Okazuka, Kiyoshi
Hatano, Kaoru
Sato, Kazuya
Oh, Lekuni
Fujiwara, Shin-Ichiro
Ohmine, Ken
Suzuki, Takahiro
Muroi, Kazuo
Kanda, Yoshinobu
LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2541 - 2547

← 1 2 3 4 5 →